查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球疫苗市场：2024年
市场调查报告书
商品编码
1431793

全球疫苗市场：2024年

The World Market for Vaccines, 2024
出版日期: | 出版商: Kalorama Information | 英文 202 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

疫苗提供针对疾病的长期或永久免疫力。70 多年来，疫苗一直是预防医学的基石，可刺激针对特定疾病的免疫反应。有效疫苗的广泛普及几乎消除了许多致命疾病，使疫苗接种成为 20 世纪最伟大的公共卫生成就之一。

由于公共免疫计划，疫苗可预防的疾病和相关死亡现在在已开发国家很少见，并且在全球范围内正在下降。天花已被消灭，小儿麻痹已在美洲消灭，麻疹、德国麻疹、破伤风、白喉、B型流感嗜血桿菌等疾病已被控制。除了预防疾病和死亡之外，疫苗还可以提高生活品质和生产力。它透过预防疾病爆发和降低医疗成本提供了显着的社会效益。

该报告考察了全球疫苗市场，并对成人和儿童预防疫苗进行了最新、全面的分析。我们还调查疫苗类别的市场预测、公司股票数据、专家的市场预测以及用于预防各种疾病的人类疫苗的市场趋势。我们特别关注那些已经可以透过疫苗预防的疾病，包括商业上可用的和正在开发的疾病。

目录

第一章执行摘要

第二章 疫苗简介

  • 介绍
  • 传记：疫苗开发
  • 人体免疫系统
  • 疫苗作用机制
  • 疫苗类型
  • 减毒（减毒）活病毒
  • 死（灭活）病毒
  • 类毒素疫苗
  • 基因重组/改良疫苗
  • 亚单位疫苗
  • 结合疫苗
  • 脱氧核糖核酸疫苗
  • 信使RNA疫苗
  • 重组载体疫苗
  • 疫苗的分类
  • 疫苗审批流程
  • FDA EUA 批准
  • 世界卫生组织认证的疫苗
  • 大流行
  • HIN1 2009/2010 年大流行
  • 冠状病毒大流行
  • 伊波拉出血热爆发
  • 製造业激励措施
  • 合成疫苗
  • 人工智慧发展

第三章 儿童预防疫苗

  • 介绍
  • 美国的儿童免疫接种
  • 儿童免疫接种率
  • 疫苗输送系统面临的挑战
  • 建议的儿童免疫计划
  • 各州的免疫接种建议
  • COVID-19 疫苗接种时间表
  • 联合国的努力
  • 儿科疫苗市场
  • 竞争概况

第四章 成人预防疫苗

  • 介绍
  • 建议的成人免疫接种
  • 全球流感监测计划
  • 美国监视
  • 世界卫生组织 国际卫生条例
  • 成人预防疫苗市场
  • 市场：占成人非 COVID-19 疫苗总销量的 26%
  • 流感
  • 竞争概况

第五章疫苗整体市场

  • 推动疫苗市场的趋势
  • 市场规模及预测
  • 儿科疫苗
  • 成人疫苗
  • 估计并预测 COVID-19 市场规模
  • 各地区疫苗销售状况
  • 世界其他地区
  • 美国
  • 欧洲
  • 疫苗市场的竞争对手
  • 疫苗产业新闻
  • 正在开发的疫苗
  • COVID-19 疫苗开发

第六章 公司简介

  • AstraZeneca
  • Bavarian Nordic, A/S
  • Bharat Biotech International Ltd.
  • Bio Farma
  • BioNTech SE
  • CSL Limited/Seqirus
  • Dynavax Technologies
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson/Crucell/Janssen
  • Merck & Co, Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer, Inc.
  • Sanofi Pasteur
  • Serum Institute, Inc.
  • Sinovac Biotech Ltd.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Co, Ltd.
  • Valneva SE
简介目录
Product Code: 24-012

Vaccines offer long-term or permanent immunity against diseases. They have been a cornerstone of preventive medicine for over 70 years, stimulating an immune response to specific diseases. The widespread adoption of effective vaccines has led to the near-elimination of many deadly diseases, making vaccination one of the greatest public health achievements of the 20th century.

Thanks to public vaccination programs, vaccine-preventable diseases and related deaths are now rare in developed nations and decreasing globally. Smallpox has been eradicated, polio eliminated in the Americas, and diseases like measles, rubella, tetanus, diphtheria, and Haemophilus influenzae type b controlled. Beyond preventing illness and death, vaccines also improve quality of life and productivity. They help prevent disease outbreaks and reduce healthcare costs, providing significant societal benefits.

Kalorama Information's latest report, "The World Market for Vaccines, 2024", offers the most up-to-date and comprehensive analysis of adult and pediatric preventative vaccines. Since the early 2000s, Kalorama has consistently published new editions of The World Market for Vaccines every two years. The report includes market forecasts, company market share data, and expert market estimates for different vaccine categories.

"The World Market for Vaccines, 2024" also examines market trends for human vaccines used to prevent various diseases. It specifically focuses on both commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Additionally, the report discusses selected emerging vaccines in development.

Vaccines covered in the report with sizing and market share include:

  • Combinations (tetanus, pertussis, Hib, Hepatitis, polio)
  • Hepatitis
  • HPV
  • Influenza
  • Meningitis
  • Pandemic vaccines/COVID-19
  • Pneumococcal
  • Rotavirus
  • RSV
  • Shingles
  • Others (travel, endemic, etc.)

The report also examines key companies involved in the market. Companies profiled in the report include:

  • AstraZeneca
  • Bavarian Nordic, A/S
  • Bharat Biotech International Ltd.
  • Bio Farma
  • BioNTech SE
  • CSL Limited/Seqirus
  • Dynavax Technologies
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson/Crucell/Janssen
  • Merck & Co, Inc.
  • Moderna, Inc
  • Novavax, Inc.
  • Pfizer, Inc.
  • Sanofi Pasteur
  • Serum Institute, Inc.
  • Sinovac Biotech Ltd.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Co, Ltd.
  • Valneva SE

Scope and Methodology

"The World Market for Vaccines, 2024" examines the market for human vaccines used to prevent various types of disease. It focuses on commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable, with a discussion of selected emerging vaccines. It also covers the COVID-19 vaccine market landscape and estimated market opportunity during the forecast period. This report does not include therapeutic vaccines such as allergy and cancer vaccines.

Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the 2023 year and forecasts are provided for 2028. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts' reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants' point of view and assess trends and form the basis of the forecasting and competitive analysis.

It should also be noted that due to the very broad scope of this report, with the exception of healthcare spending forecasts, data provided is representative but is not intended to be exhaustive. This includes, for example, tables of vaccines in development and regional economic indicators, etc. Additionally, some statistics, such as those related to venture capital investment, are subject to wide divergences across different sources; where data could not be confidently obtained, trends were discussed rather than absolute numerical values.

Table of Contents

Chapter 1: Executive Summary

  • The Global Vaccines Industry
  • Scope and Methodology
  • Market Estimates and Forecasts
    • Figure 1-1: Global Vaccine Market (Non-COVID Vaccine Market; COVID Vaccine Market), 2023-2028 ($M)
    • Figure 1-2: Regional Non-COVID vs COVID Vaccine Markets, 2018-2028 ($)
  • Competitive Analysis

Chapter 2: Introduction to Vaccines

  • Introduction
    • Table 2-1: Global Reported Cases of Vaccine Preventable Diseases, 2000 vs. 2022
    • Figure 2-1: CDC Infographic: Global Impact of Vaccines in Reducing Vaccine-Preventable Disease Morbidity and Mortality
  • A Brief History: The Development of Vaccines
  • The Human Immune System
  • Vaccine Mechanism of Action
  • Types of Vaccines
  • Attenuated (Weakened) Live Viruses
    • Figure 2-2: Attenuated Virus Production
  • Killed (Inactivated) Viruses
  • Toxoid Vaccines
  • Genetically Engineered/Modified Vaccines
  • Subunit Vaccines
  • Conjugate Vaccines
  • DNA Vaccines
  • Messenger RNA Vaccines
  • Recombinant Vector Vaccines
  • Classification of Vaccines
  • Vaccine Approval Process
    • Figure 2-3: Global Vaccine Sales by Region, 2023
  • FDA EUA Approval
  • World Health Organization Prequalified Vaccines
    • Table 2-3: WHO Prequalified BCG Vaccines
    • Table 2-4: WHO Prequalified Cholera Vaccines
    • Table 2-5: WHO Prequalified Diphtheria-Tetanus Vaccines
    • Table 2-6: WHO Prequalified Diphtheria-Tetanus-Pertussis Vaccines
    • Table 2-7: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hemophilus influenzae type b Vaccines
    • Table 2-8: WHO Prequalified Diphtheria-Tetanus-Pertussis and Hepatitis B Vaccines
    • Table 2-9: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hepatitis B-Hemophilus influenzae type b Vaccines
    • Table 2-10: WHO Prequalified Hemophilus influenzae type b Vaccines
    • Table 2-11: WHO Prequalified Hepatitis A Vaccines
    • Table 2-12: WHO Prequalified Hepatitis B Vaccines
    • Table 2-13: WHO Prequalified Human Papillomavirus Vaccines
    • Table 2-14: WHO Prequalified Influenza Vaccines
    • Table 2-15: WHO Prequalified Japanese Encephalitis Vaccines
    • Table 2-16: WHO Prequalified Measles Vaccines
    • Table 2-17: WHO Prequalified Measles and Rubella Vaccines
    • Table 2-18: WHO Prequalified Measles, Mumps and Rubella Vaccines
    • Table 2-19: WHO Prequalified Meningococcal A Vaccines
    • Table 2-20: WHO Prequalified Pneumococcal Vaccines
    • Table 2-21: WHO Prequalified Polio Vaccines
    • Table 2-22: WHO Prequalified Rabies Vaccines
    • Table 2-23: WHO Prequalified Rotavirus Vaccines
    • Table 2-24: WHO Prequalified Rubella Vaccines
    • Table 2-25: WHO Prequalified Tetanus Toxoid Vaccines
    • Table 2-26: WHO Prequalified Typhoid Vaccines
    • Table 2-27: WHO Prequalified Varicella Vaccine
    • Table 2-28: WHO Prequalified Yellow Fever Vaccines
    • Table 2-29: WHO Prequalified Other Vaccines
  • Pandemics
  • HIN1 Pandemic of 2009/2010
  • Coronavirus Pandemic
    • Figure 2-4: Leading COVID-19 Vaccines: Supplied Dose Estimates
  • Ebola Epidemics
  • Manufacturing Incentives
  • Synthetic Vaccines
  • Artificial Intelligence Development

Chapter 3: Pediatric Preventative Vaccines

  • Introduction
    • Table 3-1: Immunization Rates for Vaccines Recommended by the WHO, 2022
  • Childhood Immunization in the United States
  • Childhood Immunization Rates
  • Challenges to the Vaccine Delivery System
  • Recommended Childhood Immunization Schedule
    • Figure 3-1: CDC Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024
    • Figure 3-2: CDC Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2024
  • State Immunization Recommendations
    • Figure 3-3: Exemptions Permitted for State Childcare and School (Grades PreK-12) Immunization Requirements, United States, March 2023
  • COVID-19 Vaccination Schedule
  • United Nations Initiatives
  • Pediatric Vaccine Markets
    • Table 3-2: Global Market for Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023-2028 ($M)
    • Figure 3-4: Global Market for Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023-2028 (%)
    • Figure 3-5: Market Share of Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023 (%)
  • Competitive Summary
    • Table 3-3: Major Manufacturers' Shares of the Global Pediatric Preventative Vaccine Market, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%, $M)
    • Figure 3-6: Global Pediatric Preventative Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023, (%)

Chapter 4: Adult Preventative Vaccines

  • Introduction
  • Recommended Adult Immunizations
    • Figure 4-1: CDC Recommended Immunization Schedule: Adults, 19 years and over
  • Global Influenza Surveillance Program
  • U.S. Surveillance
    • Table: 4-1: U.S. Influenza Vaccine Effectiveness, 2004-2023 (%)
    • Figure 4-2: U.S. Influenza Vaccine Effectiveness, by Season, 2009-2023, (%)
  • WHO International Health Regulations
  • Adult Preventive Vaccine Markets
    • Table 4-2: Global Market for Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2023-2028 ($M)
    • Figure 4-3: Global Market for Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other), 2023-2028 (%)
    • Figure 4-4: Market Share of Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2023 (%)
  • Market: Generating 26% of Total Adult Non-COVID Vaccine Sales
    • Figure 4-5: U.S. Seasonal Influenza Vaccination, by Age Group and Season, 2010-2023 (%)
    • Figure 4-6: U.S. Seasonal Influenza Vaccination Coverage and HP 2020 Target - Total Population - Seasons, 2010-2023 (%)
  • Influenza
    • Figure 4-7: Estimated U.S. Flu Burden, by Season 2010-2023
    • Table 4-3: Estimated Number of Influenza Illnesses Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Table 4-4: Estimated Number of Influenza Medical Visits Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Table 4-5: Estimated Number and Fraction of Influenza Hospitalizations Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Table 4-6: Estimated Number of Influenza Deaths Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Figure 4-8: Estimated U.S. Flu Burden Prevented by Vaccination (Deaths, Hospitalizations, Medical Visits, Symptomatic Illness), 2010-2023
    • Table 4-7: WHO Pandemic Classification Schedule
  • Competitive Summary
    • Table 4-8: Major Manufacturers' Shares of the Global Adult Preventative Vaccine Market, by Company (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%, $M)
    • Figure 4-9: Global Adult Preventative Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%)

Chapter 5: Total Vaccines Market

  • Trends Driving the Vaccines Market
    • Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals, 2015-2025
  • Market Size and Forecast
    • Table 5-1: Total Global Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
    • Figure 5-2: Total World Market for Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]),, 2023-2028 (Pediatric, Adult) (SM)
    • Figure 5-3: Total World Vaccine Market, Non-COVID and COVID Vaccine, 2023-2028 ($M)
  • Pediatric Vaccines
  • Adult Vaccines
    • Figure 5-4: Global Preventive Vaccine Market, by Broad Segment (Pediatric, Adult), Trend 2018-2028 ($M)
  • COVID-19 Market Size Estimates and Forecast
    • Table 5-2: Global COVID-19 Vaccine Market Cumulative Value, 2020-2023 ($M)
    • Figure 5-5: Global COVID-19 Vaccine by Unit Volume, Cumulative 2020-2023, Estimated Distribution by Country (Australia, Brazil, Canada, China, European Union, India, Japan, Russia, South Africa, South Korea, United States, Other Countries)
  • Vaccine Sales by Region
  • Rest of World
    • Table 5-3: Total ROW Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
  • United States
    • Table 5-4: Total U.S. Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
  • Europe
    • Table 5-5: Total Europe Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
  • Vaccine Market Competitors
    • Table 5-6: Major Manufacturers' Shares of the Global Vaccine Market, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, J&J/Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinova, Other), 2023 (%, $M)
    • Figure 5-6: Global Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, J&J/Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinova, Other), 2023 (%)
  • Vaccine Industry News
  • Vaccines in Development
  • COVID-19 Vaccine Development
    • Figure 5-7: Regional Distribution of COVID-19 Vaccine Development, by Country and Region (Australia, Brazil, Canada, China, France, Indonesia, Japan, Mexico, Middle East, Philippines, Rest of Africa, Rest of Pacific, Rest of Europe, Rest of Latin America, South Africa, South Korea, United Kingdom, United States)
    • Table 5-7: Selected Vaccines in Development, 2023

Chapter 6: Company Profiles

  • AstraZeneca
    • Table 6-1: AstraZeneca Corporate Summary
      • Company Summary
      • Products
  • Bavarian Nordic, A/S
    • Table 6-2: Bavarian Nordic A/S Corporate Summary
      • Company Summary
      • Products
  • Bharat Biotech International Ltd.
    • Table 6-3: Bharat Biotech Corporate Summary
      • Company Summary
      • Products
  • Bio Farma
    • Table 6-4: Bio Farma Corporate Summary
      • Company Summary
      • Products
  • BioNTech SE
    • Table 6-5: BioNTech Corporate Summary
      • Company Summary
      • Products
  • CSL Limited/Seqirus
    • Table 6-6: CSL/Seqirus Corporate Summary
      • Company Summary
      • Products
  • Dynavax Technologies
    • Table 6-7: Dynavax Technologies Corporate Summary
      • Company Summary
      • Products
  • Emergent BioSolutions, Inc.
    • Table 6-8: Emergent BioSolutions Corporate Summary
      • Company Summary
      • Products
  • GlaxoSmithKline, Inc.
    • Table 6-9: GlaxoSmithKline Corporate Summary
      • Company Summary
      • Products
    • Table 6-10: GSK Marketed Vaccines, 2024
  • Inovio Pharmaceuticals, Inc.
    • Table 6-11: Inovio Corporate Summary
      • Company Summary
      • Products
  • Johnson & Johnson/Crucell/Janssen
    • Table 6-12: Johnson & Johnson Corporate Summary
      • Company Summary
      • Products
  • Merck & Co, Inc.
    • Table 6-13: Merck Corporate Summary
      • Company Summary
      • Products
  • Moderna, Inc.
    • Table 6-14: Moderna Corporate Summary
      • Company Summary
      • Products
  • Novavax, Inc.
    • Table 6-15: Novavax Corporate Summary
      • Company Summary
      • Products
  • Pfizer, Inc.
    • Table 6-16: Pfizer Corporate Summary
      • Company Summary
      • Products
  • Sanofi Pasteur
    • Table 6-17: Sanofi Pasteur Corporate Summary
      • Company Summary
      • Products
  • Serum Institute, Inc.
    • Table 6-18: Serum Institute of India Corporate Summary
      • Company Summary
      • Products
  • Sinovac Biotech Ltd.
    • Table 6-19: Sinovac Biotech Corporate Summary
      • Company Summary
      • Products
  • Soligenix, Inc.
    • Table 6-20: Soligenix Corporate Summary
      • Company Summary
      • Products
  • Takeda Pharmaceutical Co, Ltd.
    • Table 6-21: Takeda Pharmaceutical Corporate Summary
      • Company Summary
      • Products
  • Valneva SE
    • Table 6-22: Valneva Corporate Summary
      • Company Summary
      • Products